Results 101 to 110 of about 192,321 (311)
Molecular Oncology, EarlyView.Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
Targeted inhibition of cancer-inflammation [PDF]
, 2012 The new paradigm in cancer treatment that aims to inhibit the smoldering inflammatory response in tumors is explored to develop new anticancer treatments.
Pharmaceutics +2 more
core
Drug targeting to the diseased liver [PDF]
, 2012 Many serious liver diseases affecting millions of people world-wide cannot be treated despite many efforts which warrants a search for new therapeutic strategies.
Beljaars, Leonie; id_orcid +4 more
core +1 more source
Translating whole‐genome doubling into precision medicine in cancer
Molecular Oncology, EarlyView.Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley +1 more source
Molecular Oncology, EarlyView.Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant +11 more
wiley +1 more source
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations [PDF]
The strategy of drug repositioning has historically played a significant role in the identification of new treatments for Parkinson's disease. Still today, numerous clinical and preclinical studies are investigating drug classes, already marketed for the
DiLuca, Monica +2 more
core +1 more source
Tools to investigate and avoid drug-hypersensitivity in drug development [PDF]
, 2018 Drug hypersensitivity reactions (DHRs) are common adverse effects of pharmaceuticals that clinically resemble allergies, and which are becoming an important burden to healthcare systems.
M. Casula +4 more
core +1 more source
Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies
ADMET and DMPKBackground and purpose: The delivery of therapeutics to the central nervous system (CNS) remains a major challenge due to the restrictive nature of the blood-brain barrier (BBB), a key evolutionary feature that preserves brain homeostasis.
Ronny Vargas +8 more
doaj +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Molecular Oncology, EarlyView.Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Drug Design, Development and TherapyQianlei Ye,1,2,* Wei Xing,2,* Xuefeng Hu,2 Wenjuan Liu,2 Jigang Wu,2 Hailan Huang,2 Ying Xiao,2 Yanjun Hong1 1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, People’s Republic of China; 2Shenzhen Salubris ...
Ye Q +7 more
doaj